Murali Pandey

Dr. Murali Pandey

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Process Biochemistry
Verified
Journal Article
Closed access
SDSunil Kumar Dubey
Sunil Kumar Dubey
SPShraddha Parab
Shraddha Parab
AAAmit Alexander
Amit Alexander
MAMukta Agrawal
Mukta Agrawal
VAVaishnav Pavan Kumar Achalla
Vaishnav Pavan Kumar Achalla
PKPrashant Kesharwani
Prashant Kesharwani

9 May 2023 in Journal of Controlled Release
Verified
Journal Article
Closed access
PSParamita Saha
Paramita Saha
HKHimanshu Kathuria
Himanshu Kathuria
MPMurali Pandey
Murali Pandey

5 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PSParamita Saha
Paramita Saha
PSPrabhjeet Singh
Prabhjeet Singh
HKHimanshu Kathuria
Himanshu Kathuria
DCDeepak Chitkara
Deepak Chitkara
MPMurali Pandey
Murali Pandey
Rotigotine (RTG) is a non-ergoline dopamine agonist and an approved drug for treating Parkinson’s disease. However, its clinical use is limited due to various problems, viz. poor oral bioavailability (<1%), low aqueous solubility, and extensive first-pass metabolism. In this study, rotigotine-loaded lecithin-chitosan nanoparticles (RTG-LCNP) were formulated to enhance its nose-to-brain delivery. RTG-LCNP was prepared by self-assembly of chitosan and lecithin due to ionic interactions. The optimized RTG-LCNP had an average diameter of 108 nm with 14.43 ± 2.77% drug loading. RTG-LCNP exhibited spherical morphology and good storage stability. Intranasal RTG-LCNP improved the brain availability of RTG by 7.86 fold with a 3.84-fold increase in the peak brain drug concentration (Cmax(brain)) compared to intranasal drug suspensions. Further, the intranasal RTG-LCNP significantly reduced the peak plasma drug concentration (Cmax(plasma)) compared to intranasal RTG suspensions. The direct drug transport percentage (DTP (%)) of optimized RTG-LCNP was found to be 97.3%, which shows effective direct nose-to-brain drug uptake and good targeting efficiency. In conclusion, RTG-LCNP enhanced drug brain availability, showing the potential for clinical application.

16 June 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
NHNikita Subhash Hinge
Nikita Subhash Hinge
HKHimanshu Kathuria
Himanshu Kathuria
MPMurali Pandey
Murali Pandey

29 November 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
PSParamita Saha
Paramita Saha
HKHimanshu Kathuria
Himanshu Kathuria
MPMurali Pandey
Murali Pandey

15 March 2021 in Journal of Chromatographic Science
Verified
Journal Article
Closed access
PDF file
PSParamita Saha
Paramita Saha
MPMurali Pandey
Murali Pandey
Present study reports design of experiment (DoE) based development and validation of a simple, rapid and sensitive reversed-phase high-performance liquid chromatography (RP-HPLC) method for estimation of efavirenz (EFZ), a non-nucleotide reverse transcriptase inhibitor (NNRTs), used in the treatment of acquired immunodeficiency syndrome (AIDS). Plackett–Burman design was explored to screen the critical method variables (CMVs) for the RP-HPLC method. A response surface Box–Behnken design was employed to optimize the screened CMVs which affect the analytical responses (ARs) of RP-HPLC method. Using the optimized CMVs the HPLC method was developed and validated according to International Conference on Harmonization (ICH) guidelines. EFZ in marketed formulation was estimated using the validated method. Acetonitrile proportion, pH of the phosphate buffer and mobile phase flow rate were the CMVs and retention time and number of theoretical plates were the ARs for the study. The optimized chromatographic parameters were acetonitrile proportion in mobile phase: 51.17%v/v, pH of phosphate buffer: 4.04 and flow rate: 1.25 mL/min. Use of these optimized parameters resulted in retention time of 11.031 min and 9,498.787 number of theoretical plates as ARs of the HPLC method. The method was further validated in harmony with current ICH guidelines Q2 (R1). The method was capable of the successful estimation of EFZ in marketed formulation. The study depicts successful development and validation of a simple RP-HPLC method of EFZ using DoE approach.